Min Seok Baek1, Hanna Cho1, Hye Sun Lee2, Jae Yong Choi3,4, Jae Hoon Lee3, Young Hoon Ryu5, Myung Sik Lee1, Chul Hyoung Lyoo6. 1. Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. 2. Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, South Korea. 3. Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. 4. Division of RI-Convergence Research, Korea Institute Radiological and Medical Sciences, Seoul, South Korea. 5. Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. ryuyh@yuhs.ac. 6. Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. lyoochel@yuhs.ac.
Abstract
PURPOSE: To investigate the temporal trajectories of tau and amyloid-β (Aβ) accumulation in Alzheimer's disease (AD) by using the longitudinal positron emission tomography (PET) study. METHODS: A total of 132 participants, who were healthy volunteers or recruited in our memory disorder clinic, completed longitudinal 18F-flortaucipir and 18F-florbetaben PET studies with a mean follow-up time of 2 years. Referencing baseline data from 57 Aβ-negative cognitively unimpaired individuals, Z-scores and their annual changes were calculated with the global cortical or regional standardized uptake value ratios measured at baseline and follow-up after correcting for partial volume effect. The temporal trajectories of tau and Aβ burden as a function of time were obtained based on the spline models from the annual changes and baseline Z-score data. RESULTS: Tau burden first emerged in the Braak's stage I-II regions, followed by stage III-IV regions, and finally in the stage V-VI regions. Time intervals between two time points at which Z-score curves rose above 2 were 17.3 years for the stages I-II and III-IV and 15.2 years for the stages III-IV and V-VI. Rise in the tau curve for stages I-II preceded that for global cortical Aβ, while the rise in global cortical Aβ curve preceded that for global cortical tau. Aβ accumulation rate was attenuated during the surge in tau burden in the global cortex and reached a plateau. CONCLUSION: Sequential appearance of Aβ and tau accumulation supports a hypothetical dynamic biomarker model and Braak's hierarchical tau spreading model in AD.
PURPOSE: To investigate the temporal trajectories of tau and amyloid-β (Aβ) accumulation in Alzheimer's disease (AD) by using the longitudinal positron emission tomography (PET) study. METHODS: A total of 132 participants, who were healthy volunteers or recruited in our memory disorder clinic, completed longitudinal 18F-flortaucipir and 18F-florbetaben PET studies with a mean follow-up time of 2 years. Referencing baseline data from 57 Aβ-negative cognitively unimpaired individuals, Z-scores and their annual changes were calculated with the global cortical or regional standardized uptake value ratios measured at baseline and follow-up after correcting for partial volume effect. The temporal trajectories of tau and Aβ burden as a function of time were obtained based on the spline models from the annual changes and baseline Z-score data. RESULTS: Tau burden first emerged in the Braak's stage I-II regions, followed by stage III-IV regions, and finally in the stage V-VI regions. Time intervals between two time points at which Z-score curves rose above 2 were 17.3 years for the stages I-II and III-IV and 15.2 years for the stages III-IV and V-VI. Rise in the tau curve for stages I-II preceded that for global cortical Aβ, while the rise in global cortical Aβ curve preceded that for global cortical tau. Aβ accumulation rate was attenuated during the surge in tau burden in the global cortex and reached a plateau. CONCLUSION: Sequential appearance of Aβ and tau accumulation supports a hypothetical dynamic biomarker model and Braak's hierarchical tau spreading model in AD.
Entities:
Keywords:
18F-flortaucipir; Alzheimer’s disease; Positron emission tomography; Tau
Authors: Wha Jin Lee; Jesse A Brown; Hye Ryun Kim; Renaud La Joie; Hanna Cho; Chul Hyoung Lyoo; Gil D Rabinovici; Joon-Kyung Seong; William W Seeley Journal: Neuron Date: 2022-04-19 Impact factor: 18.688
Authors: Alexis Moscoso; Michel J Grothe; Nicholas J Ashton; Thomas K Karikari; Juan Lantero Rodriguez; Anniina Snellman; Marc Suárez-Calvet; Henrik Zetterberg; Kaj Blennow; Michael Schöll Journal: Brain Date: 2021-02-12 Impact factor: 13.501
Authors: E E Wolters; A Dodich; M Boccardi; J Corre; A Drzezga; O Hansson; A Nordberg; G B Frisoni; V Garibotto; R Ossenkoppele Journal: Eur J Nucl Med Mol Imaging Date: 2021-02-06 Impact factor: 9.236
Authors: Myung Jun Lee; Kyoungjune Pak; Han-Kyeol Kim; Kelly N Nudelman; Jong Hun Kim; Yun Hak Kim; Junho Kang; Min Seok Baek; Chul Hyoung Lyoo Journal: NPJ Parkinsons Dis Date: 2021-11-26
Authors: Jun Pyo Kim; Min Young Chun; Soo-Jong Kim; Hyemin Jang; Hee Jin Kim; Jee Hyang Jeong; Duk L Na; Sang Won Seo Journal: Front Aging Neurosci Date: 2022-02-07 Impact factor: 5.750
Authors: Hugh G Pemberton; Lyduine E Collij; Fiona Heeman; Ariane Bollack; Mahnaz Shekari; Gemma Salvadó; Isadora Lopes Alves; David Vallez Garcia; Mark Battle; Christopher Buckley; Andrew W Stephens; Santiago Bullich; Valentina Garibotto; Frederik Barkhof; Juan Domingo Gispert; Gill Farrar Journal: Eur J Nucl Med Mol Imaging Date: 2022-04-07 Impact factor: 10.057